Clear All
754 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9416 BCG BCG, Intravesical Per instillation Immunotherapy Biological Response Modifier Live Vaccine No 1990 Jan 1, 2004 Dec 31, 2003 No Longer Used
J9180 Epirubicin Epirubicin 50 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1999 Jan 1, 2001 Dec 31, 2003 No Longer Used
NA Polyestradiol Phosphate Estradurin, Estradurine 40 mg Hormonal Therapy Estrogen Derivative No 1957 Aug 8, 2003 No Longer Used
C9118 Ibritumomab tiuxetan Zevalin Per MCI Immunotherapy Radioimmunotherapy CD20 No 2002 Oct 1, 2002 Dec 31, 2002 No Longer Used
S0087 Alemtuzumab Campath 30 mg Immunotherapy Monoclonal Antibody CD52 No 2001 2012 Jan 1, 2002 Dec 31, 2002 No Longer Used
C9117 Ibritumomab tiuxetan Zevalin Per MCI Immunotherapy Radioimmunotherapy CD20 No 2002 Oct 1, 2002 Dec 31, 2002 No Longer Used
C9012 Arsenic Trioxide Trisenox unspecified Chemotherapy Miscellaneous Agent PML/RARa No 2000 Jan 1, 2001 Dec 31, 2001 No Longer Used
C9069 Belantamab mafodotin-blmf Blenrep 0.5mg Immunotherapy Drug Antibody Conjugate BCMA No 2020 Jan 1, 2021 No Longer Used
S0182 Procarbazine Matulane 50 mg Chemotherapy Alkylating Agent Benzamide Yes 1969 Jan 1, 2002 In Use
NA Anagrelide Agrylin 0.5mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
Q2054 Lisocabtagene maraleucel Breyanzi Immunotherapy CAR-T CD19 No 2021 Sep 27, 2021 In Use
J9046 Bortezomib (Dr Reddy) Bortezomib (Dr Reddy) 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2022 Dec 21, 2022 In Use
J9048 Bortezomib (Fresniuskab) Bortezomib (Fresniuskab) 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2017 Dec 21, 2022 In Use
NA Acalabrutinib Calquence 100 mg Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Yes 2017 In Use
J9302 Ofatumumab Arzerra 10mg Immunotherapy Monoclonal Antibody CD20 No 2009 Jan 1, 2011 In Use
Maribavir Livtencity 200mg Ancillary Therapy Miscellaneous Agent CMV Antiviral Yes 2021 In Use
Q2058 Obecabtagene autoleucel AUCATZYL up to 400 million Immunotherapy CAR-T CD-19 No 2024 May 13, 2025 In Use
NA Avapritinib Ayvakit 300mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
J1950 Leuprolide Acetate Eligard, Lupron Depot, Viadur, Lupron 3.75 mg Hormonal Therapy GnRH Agonist No 1989 Jan 1, 1997 In Use
NA Belumosudil Rezurock 200mg Chemotherapy Rho Kinase Inhibitor ROCK1, ROCK2 Yes 2021 In Use
J9289 Nivolumab and hyaluronidase-nvhy OPDIVO QVANTIG 2mg Immunotherapy Checkpoint Inhibitor PD-1 No 2025 May 13, 2025 In Use
NA Letrozole Femara 2.5 mg Hormonal Therapy Aromatase Inhibitor Yes 1997 In Use
J9356 Trastuzumab and Hyaluronidase-oysk Herceptin hylecta 10mg Immunotherapy Monoclonal Antibody HER2 No 2019 Jul 1, 2019 In Use
J9292 Pemetrexed dipotassium Pemetrexed Dipotassium 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2025 Jan 1, 2025 In Use
NA Avapritinib Ayvakit 25mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.